China Pharma Holding Inc. is a Nevada holding company that conducts all of its operations through its wholly owned subsidiary Hainan Helpson Medical & Biotechnology Co Ltd in the People's Republic of China. Helpson develops, manufactures, and markets pharmaceutical products for human use including dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions targeting high incidence and high mortality diseases. In addition Helpson offers…
China Pharma Holding Inc. is a Nevada holding company that conducts all of its operations through its wholly owned subsidiary Hainan Helpson Medical & Biotechnology Co Ltd in the People's Republic of China. Helpson develops, manufactures, and markets pharmaceutical products for human use including dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions targeting high incidence and high mortality diseases. In addition Helpson offers healthcare products such as Noni enzyme, a natural antioxidant food supplement, and medical masks, sanitizers, and related personal protective equipment. The company operates within the pharmaceutical and healthcare sector in China.
Revenue comes from selling pharmaceutical products such as Candesartan tablets for hypertension, Gastrodin Injection for cerebrovascular support, Cefaclor Dispersible Tablets for antibiotic treatment, Omeprazole for gastric acid reduction, and Vitamin B6 for Injection as a supplement. Additional revenue is generated from healthcare products including Noni enzyme, a natural antioxidant supplement, and various masks and sanitizers that address personal protective needs. The company sells these products mainly to Good Supply Practice certified distributors who then supply state owned hospitals and retail pharmacies across China.
China Pharma Holding Inc. operates in a competitive Chinese pharmaceutical market where many manufacturers vie for inclusion in national centralized procurement programs. Its competitors include other drug makers whose products have passed the consistency evaluation and won bids in centralized procurement thereby gaining pricing advantages. The company seeks to maintain relevance by pursuing consistency evaluation for its own products and by diversifying into healthcare items such as masks, and supplements that are less subject to procurement price pressures. Helpson’s NMPA approvals for its core drugs, and its production capacity for protective equipment provide certain competitive strengths.
The customer base consists principally of Good Supply Practice certified distributors that purchase the company’s products for resale to state owned hospitals. These distributors operate throughout China and serve urban, and rural healthcare facilities. For its over the counter healthcare products such as masks, sanitizers, and Noni enzyme the company also reaches retail pharmacies, and individual consumers directly.
Read more ↓
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic CIK: 0001106644